Allergan (AGN +1.3%) saw a bounce in its Botox migraine share last month, according to Wells Fargo. The firm says research data for February shows it with an 8.8% market share among sample neurologists, up from 5.3% in January and 8.4% in December. Wells estimates U.S. sales are close to $300M annually, tracking ahead of estimates. The firm maintains its Outperform rating on the stock.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Nasdaq.com (Tue, 9:00AM)
at CNBC.com (Feb 18, 2015)
at CNBC.com (Feb 10, 2015)
at CNBC.com (Jan 26, 2015)
at Nasdaq.com (Jan 21, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs